A
AGRX
vs
S&P 500
S&P 500
Over the past 12 months, AGRX has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +15% growth.
Stocks Performance
AGRX vs S&P 500
Performance Gap
AGRX vs S&P 500
Performance By Year
AGRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Agile Therapeutics Inc
Glance View
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. The company is headquartered in Princeton, New Jersey and currently employs 30 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
